Unmet clinical need in autoimmune liver diseases

International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis

Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903 · see citing works

High Serum IgG4 Concentrations in Patients with Sclerosing Pancreatitis

Hamano, H., Kawa, S., Horiuchi, A., Unno, H., Furuya, N., Akamatsu, T., Fukushima, M., Nikaido, T., Nakayama, K., Usuda, N., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441005 · Cited by 2,704 · see citing works

IgG4-Related Disease

Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,618 · see citing works

Consensus statement on the pathology of IgG4-related disease

Deshpande, V., Zen, Y., Chan, J. K. C., Yi, E. E., Sato, Y., Yoshino, T., Klöppel, G., Heathcote, J. G., Khosroshahi, A., Ferry, J. A., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.72 · Cited by 2,604 · see citing works

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C

Castéra, L., Vergniol, J., Foucher, J., Bail, B. L., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., & de Lédinghen, V. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.018 · Cited by 2,480 · see citing works

EASL Clinical Practice Guidelines: management of cholestatic liver diseases

European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729 · see citing works

Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

Friedrich‐Rust, M., Ong, M. F., Martens, S., Sarrazin, C., Bojunga, J., Zeuzem, S., & Herrmann, E. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.034 · Cited by 1,488 · see citing works

Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · see citing works

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720 · see citing works

Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study

Gregorio, G. (2001) · Hepatology · doi:10.1053/jhep.2001.22131 · Cited by 692 · see citing works

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 1× · see citing works

Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview‐based study of 1032 patients

Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621 · see citing works

Primary Biliary Cirrhosis Associated with <i>HLA, IL12A,</i> and <i>IL12RB2</i> Variants

Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594 · see citing works

Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555 · see citing works

Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential

Broomé, U., Löfberg, R., VERESS, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 492 · see citing works

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis

The UK PBC Consortium, Mells, G. F., The Wellcome Trust Case Control Consortium 3, Floyd, J. A. B., Morley, K. I., Cordell, H. J., Franklin, C. S., Shin, S.-Y., Heneghan, M. A., Neuberger, J. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.789 · Cited by 464 · see citing works

Improved Prognosis of Patients With Primary Biliary Cirrhosis That Have a Biochemical Response to Ursodeoxycholic Acid

Kuiper, E. M. M., Hansen, B. E., de Vries, R. A., den Ouden–Muller, J. W., van Ditzhuijsen, T. J. M., Haagsma, E. B., Houben, M. H. M. G., Witteman, B. J. M., van Erpecum, K. J., & van Buuren, H. R. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.003 · Cited by 460 · see citing works

Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis

Manns, M. P., Woynarowski, M., Kreisel, W., Lurie, Y., Rust, C., Zuckerman, E., Bahr, M. J., Günther, R., Hultcrantz, R. W., Spengler, U., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.046 · Cited by 443 · see citing works

Natural history of early primary biliary cirrhosis

Metcalf, J. V., Mitchison, H. C., Palmer, J. M., Jones, D. E., Bassendine, M. F., & James, O. F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04410-8 · Cited by 421 · see citing works

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A., Steplewski, Z., & Pour, P. M. (1987) · PubMed · Cited by 400 · see citing works

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis

Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R., & Poupon, R. Y. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 391 · see citing works

Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic Acid

Carbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386 · see citing works

Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis

Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372 · see citing works

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365 · see citing works

Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis

Corpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351 · see citing works

The Biliary HCO3 − Umbrella: A Unifying Hypothesis on Pathogenetic and Therapeutic Aspects of Fibrosing Cholangiopathies

Beuers, U., Hohenester, S., de Buy Wenniger, L. J. M., Kremer, A. E., Jansen, P. L. M., & Elferink, R. P. J. O. (2010) · Hepatology · doi:10.1002/hep.23810 · Cited by 351 · see citing works

Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis

Corpechot, C., Gaouar, F., El Naggar, A., Kemgang, A., Wendum, D., Poupon, R., Carrat, F., & Chazouillères, O. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.030 · Cited by 300 · see citing works

Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice

Mann, D., Edwards, R. J., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0925 · Cited by 295 · see citing works

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions

Kremer, A. E., van Dijk, R., Leckie, P., Schaap, F. G., Kuiper, E. M. M., Mettang, T., Reiners, K. S., Raap, U., van Buuren, H. R., van Erpecum, K. J., et al. (2012) · Hepatology · doi:10.1002/hep.25748 · Cited by 291 · see citing works

Cancer surveillance in patients with primary sclerosing cholangitis

Razumilava, N., Gores, G. J., & Lindor, K. D. (2011) · Hepatology · doi:10.1002/hep.24570 · Cited by 290 · see citing works

Transplantation for Primary Biliary Cirrhosis: Retrospective Analysis of 400 Patients in A Single Center

Garcia, R. F. L., Garcia, C. E., McMaster, P., & Neuberger, J. (2001) · Hepatology · doi:10.1053/jhep.2001.20894 · Cited by 254 · see citing works

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: Results of a prospective double-blind trial

Leuschner, M., Maier, K., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H. H., Ackermann, H., Happ, J., & Leuschner, U. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70351-3 · Cited by 247 · see citing works

Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis

Corpechot, C., Chrétien, Y., Chazouillères, O., & Poupon, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.019 · Cited by 235 · see citing works

Impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study

Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology · doi:10.1002/hep.26365 · Cited by 227 · see citing works

ABH and Lewis histo‐blood group antigens in cancer

LePendu, J., Marionneau‐Lambot, S., Cailleau–Thomas, A., Rocher, J., Moullac‐Vaidye, B. L., & Clément, M. (2001) · Apmis · doi:10.1111/j.1600-0463.2001.tb00011.x · Cited by 226 · see citing works

Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites

Ala, A., Stanca, C. M., Bu-Ghanim, M., Ahmado, I., Branch, A. D., Schiano, T. D., Odin, J. A., & Bach, N. (2006) · Hepatology · doi:10.1002/hep.21076 · Cited by 222 · see citing works

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial†

Rautiainen, H., Kärkkäinen, P., Karvonen, A., Nurmi, H., Pikkarainen, P., Nuutinen, H., & Färkkilä, M. (2005) · Hepatology · doi:10.1002/hep.20646 · Cited by 222 · see citing works

Familial primary biliary cirrhosis reassessed: a geographically-based population study

Jones, D. E., Watt, F. E., Metcalf, J. V., Bassendine, M. F., & James, O. F. W. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80097-x · Cited by 213 · see citing works

Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center

Hoeroldt, B., McFarlane, E., Dubé, A., Basumani, P., Karajeh, M. A., Campbell, M. J., & Gleeson, D. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.065 · Cited by 207 · see citing works

Features of Autoimmune Hepatitis in Primary Sclerosing Cholangitis: An Evaluation of 114 Primary Sclerosing Cholangitis Patients According to A Scoring System for the Diagnosis of Autoimmune Hepatitis

Boberg, K. M., FAUSA, O., Haaland, T., Holter, E., Mellbye, O. J., Spurkland, A., & Schrumpf, E. (1996) · Hepatology · doi:10.1002/hep.510230612 · Cited by 204 · see citing works

Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

Mamari, S. A., Djordjevic, J., Halliday, J., & Chapman, R. W. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.013 · Cited by 202 · see citing works

The Pruritus of Cholestasis

Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202 · see citing works

The true impact of fatigue in primary biliary cirrhosis: A population study

Goldblatt, J., Taylor, P. J. S., Lipman, T., Prince, M. I., Baragiotta, A., Bassendine, M. F., James, O. F. W., & Jones, D. E. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32993 · Cited by 202 · see citing works

Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis

Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202 · see citing works

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

Mayo, M. J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A. S., Markin, R. S., Rubin, R., Wheeler, D., Contos, M., West, A. B., et al. (2008) · Hepatology · doi:10.1002/hep.22517 · Cited by 198 · see citing works

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

Chazouillères, O., Wendum, D., Serfaty, L., Rosmorduc, O., & Poupon, R. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.017 · Cited by 194 · see citing works

Comparison of the Clinicopathologic Features of Primary Sclerosing Chol-angitis and Primary Biliary Cirrhosis

Wiesner, R. H., LaRusso, N. F., Ludwig, J., & Dickson, E. R. (1985) · Gastroenterology · doi:10.1016/s0016-5085(85)80141-4 · Cited by 192 · see citing works

Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis

Boonstra, K., Culver, E. L., Wenniger, L. J. M. D. B., Heerde, M. J. V., van Erpecum, K. J., Poen, A. C., van Nieuwkerk, K. M. J., Spanier, M., Witteman, B. J. M., Tuynman, H. A. R. E., et al. (2013) · Hepatology · doi:10.1002/hep.26977 · Cited by 189 · see citing works

Autoimmune hepatitis with incidental histologic features of bile duct injury

Czaja, A. J., & Carpenter, H. A. (2001) · Hepatology · doi:10.1053/jhep.2001.27562 · Cited by 189 · see citing works

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid: Pilot study: fenofibrate with UDCA for primary biliary cirrhosis

Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186 · see citing works

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

Angulo, P., Jorgensen, R. A., Keach, J. C., Dickson, R. E., Smith, C., & Lindor, K. D. (2000) · Hepatology · doi:10.1002/hep.510310209 · Cited by 179 · see citing works

The geographical distribution of primary biliary cirrhosis in a well-defined cohort

Prince, M. I., Chetwynd, A., Diggle, P., Jarner, M., Metcalf, J. V., & James, O. F. W. (2001) · Hepatology · doi:10.1053/jhep.2001.29760 · Cited by 166 · see citing works

Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population.

Vestergaard, E. M., Hein, H. O., Meyer, H., Grunnet, N., Jørgensen, J. B., Wolf, H., & Orntoft, T. F. (1999) · PubMed · Cited by 164 · see citing works

Cognitive impairment in primary biliary cirrhosis: Symptom impact and potential etiology†

Newton, J. L., Hollingsworth, K. G., Taylor, R., El‐Sharkawy, A. M., Khan, Z. U., Pearce, R., Sutcliffe, K., Okonkwo, O., Davidson, A., Burt, J., et al. (2008) · Hepatology · doi:10.1002/hep.22371 · Cited by 156 · see citing works

Biochemical and Immunologic Effects of Rituximab in Patients With Primary Biliary Cirrhosis and an Incomplete Response to Ursodeoxycholic Acid

Tsuda, M., Moritoki, Y., Lian, Z.-X., Zhang, W., Yoshida, K., Wakabayashi, K., Yang, G., Nakatani, T., Vierling, J. M., Lindor, K. D., et al. (2011) · Hepatology · doi:10.1002/hep.24748 · Cited by 151 · see citing works

IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material

Deshpande, V., Sainani, N. I., Chung, R. T., Pratt, D. S., Mentha, G., Rubbia‐Brandt, L., & Lauwers, G. Y. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.94 · Cited by 151 · see citing works

Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential*1

Broomé, U. (1995) · Hepatology · doi:10.1016/0270-9139(95)90144-2 · Cited by 150 · see citing works

Autoimmune liver disease

Czaja, A. J. (2007) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328034f234 · Cited by 147 · see citing works

Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis

Wenniger, L. J. M. D. B., Doorenspleet, M. E., Klarenbeek, P. L., Verheij, J., Baas, F., Elferink, R. P. J. O., Tak, P. P., de Vries, N., & Beuers, U. H. (2013) · Hepatology · doi:10.1002/hep.26232 · Cited by 145 · see citing works

Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment

Gotthardt, D. N., Rudolph, G., Klöters-Plachky, P., Kulaksiz, H., & Stiehl, A. (2010) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2009.10.041 · Cited by 144 · see citing works

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders

Metzger, J., Negm, A. A., Plentz, R. R., Weismüller, T. J., Wedemeyer, J., Karlsen, T. H., Dakna, M., Mullen, W., Mischak, H., Manns, M. P., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302047 · Cited by 137 · see citing works

Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis

Schramm, C., Wahl, I., Weiler-Normann, C., Voigt, K., Wiegard, C., Glaubke, C., Brähler, E., Löwe, B., Lohse, A. W., & Rose, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.10.035 · Cited by 128 · see citing works

Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis

Lazaridis, K. N., Juran, B. D., Boe, G. M., Slusser, J. P., de Andrade, M., Homburger, H. A., Ghosh, K., Dickson, R. E., Lindor, K. D., & Petersen, G. M. (2007) · Hepatology · doi:10.1002/hep.21749 · Cited by 128 · see citing works

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

Wunsch, E., Trottier, J., Milkiewicz, M., Raszeja‐Wyszomirska, J., Hirschfield, G. M., Barbier, O., & Milkiewicz, P. (2014) · Hepatology · doi:10.1002/hep.27074 · Cited by 127 · see citing works

Influence of Lewis α1-3/4-L-Fucosyltransferase (FUT3) Gene Mutations on Enzyme Activity, Erythrocyte Phenotyping, and Circulating Tumor Marker Sialyl-Lewis a Levels

Orntoft, T. F., Vestergaard, E. M., Holmes, E. H., Jakobsen, J. S., Grunnet, N., Mortensen, M., Johnson, P. H., Bross, P., Gregersen, N., Skorstengaard, K., et al. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.32260 · Cited by 126 · see citing works

B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid

Myers, R. P., Swain, M. G., Lee, S. S., Shaheen, A. A., & Burak, K. W. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.51 · Cited by 123 · see citing works

HIGH SERUM IgG4 CONCENTRATIONS IN PATIENTS WITH SCLEROSING PANCREATITIS

Ideaki, H., Amano, H., Awa, S., Oriuchi, A. K. H., Nno, H. I. U., Uruya, N. A. F., Kamatsu, T. A. A., Ukushima, M. A. F., Ikaido, T. O. N., Akayama, K., et al. (2015) · Cited by 120 · see citing works

Pathogenesis of primary biliary cirrhosis

Jones, D. E. (2007) · Postgraduate Medical Journal · doi:10.1136/gut.2007.122150 · Cited by 119 · see citing works

Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers

Parés, A. R., Herrera, M., Avilés, J., Sanz, M., & Mas, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.031 · Cited by 116 · see citing works

Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma

Fritcher, E. G. B., Kipp, B. R., Voss, J. S., Clayton, A. C., Lindor, K. D., Halling, K. C., & Gores, G. J. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.272 · Cited by 113 · see citing works

Fatigue in patients with primary sclerosing cholangitis

Bjornsson, E. S., Simrén, M., Olsson, R., & Chapman, R. W. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410003434 · Cited by 108 · see citing works

Optimising corticosteroid treatment for autoimmune pancreatitis

Ghazale, A. H., & Chari, S. T. (2007) · Gut · doi:10.1136/gut.2007.129833 · Cited by 108 · see citing works

Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment

Zein, C. O., Beatty, K., Post, A. B., Logan, L., Debanne, S. A., & McCullough, A. J. (2006) · Hepatology · doi:10.1002/hep.21423 · Cited by 104 · see citing works

Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin Concentration

Ong, S. L., Sachdeva, A., Garcea, G., Gravante, G. G., Metcalfe, M. S., Lloyd, D., Berry, D. P., & Dennison, A. R. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0289-8 · Cited by 93 · see citing works

Liver transplantation in PBC and PSC: Indications and disease recurrence

Carbone, M., & Neuberger, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.02.007 · Cited by 89 · see citing works

Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis – Overlapping or separate diseases?

Webster, G. J. M., Pereira, S. P., & Chapman, R. W. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.010 · Cited by 89 · see citing works

Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis

Czaja, A. J., Muratori, P., Muratori, L., Carpenter, H. A., & Bianchi, F. B. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0924.x · Cited by 89 · see citing works

Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis

Ludwig, J., MacCarty, R. L., LaRusso, N. F., Krom, R. A. F., & Wiesner, R. H. (1986) · Hepatology · doi:10.1002/hep.1840060403 · Cited by 83 · see citing works

Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis

Iwasaki, S. (1999) · Hepatology Research · doi:10.1016/s1386-6346(99)00033-9 · Cited by 80 · see citing works

Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis

Corpechot, C., Gaouar, F., Chrétien, Y., Johanet, C., Chazouillères, O., & Poupon, R. Y. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.031 · Cited by 75 · see citing works

Pain as a complication of use of opiate antagonists for symptom control in cholestasis

Mcrae, C. A., Prince, M. I., Hudson, M., Day, C. P., James, O. F. W., & Jones, D. E. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00879-5 · Cited by 73 · see citing works

Autoimmune hepatitis: The investigational and clinical challenges

Czaja, A. J., Manns, M. P., McFarlane, I. G., & Hoofnagle, J. H. (2000) · Hepatology · doi:10.1053/he.2000.5980 · Cited by 72 · see citing works

B cell depletion therapy exacerbates murine primary biliary cirrhosis

Dhirapong, A., Lleò, A., Yang, G., Tsuneyama, K., Dunn, R., Kehry, M. R., Packard, T. A., Cambier, J. C., Liu, F., Lindor, K. D., et al. (2010) · Hepatology · doi:10.1002/hep.24044 · Cited by 70 · see citing works

Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis

Floreani, A., Cazzagon, N., Martines, D., Cavalletto, L., Baldo, V., & Chemello, L. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.06.011 · Cited by 68 · see citing works

The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort

Pells, G., Mells, G. F., Carbone, M., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J., Day, D. B., Ducker, S. J., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.019 · Cited by 66 · see citing works

Factors That Reduce Health-Related Quality of Life in Patients With Primary Sclerosing Cholangitis

Valle, M., Rahman, M., Lindkvist, B., Bjornsson, E. S., Chapman, R. W., & Kalaitzakis, E. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.025 · Cited by 66 · see citing works

Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture

Shibata, M., Onozuka, Y., Morizane, T., Koizumi, H., Kawaguchi, N., Miyakawa, H., Kako, M., & Mitamura, K. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-003-1285-6 · Cited by 61 · see citing works

Identifying opportunities to improve management of autoimmune hepatitis: Evaluation of drug adherence and psychosocial factors

Sockalingam, S., Blank, D., Abdelhamid, N., Abbey, S. E., & Hirschfield, G. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.032 · Cited by 59 · see citing works

Pathogenesis of Primary Biliary Cirrhosis

Jones, D. E. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.004 · Cited by 58 · see citing works

Is bezafibrate histologically effective for primary biliary cirrhosis?

Yano, K., Kato, H., Morita, S., Takahara, O., Ishibashi, H., & FURUKAWA, R. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05645.x · Cited by 56 · see citing works

Autoimmune Hepatitis and Liver Transplantation: Indications, Results, and Management of Recurrent Disease

Tripathi, D., & Neuberger, J. (2009) · Seminars in Liver Disease · doi:10.1055/s-0029-1233531 · Cited by 54 · see citing works

Review article: the management of autoimmune hepatitis beyond consensus guidelines

Czaja, A. J. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12381 · Cited by 54 · see citing works

‘Out‐patient’ albumin dialysis for cholestatic patients with intractable pruritus

Leckie, P., Tritto, G., Mookerjee, R., Davies, N., Jones, D., & Jalan, R. (2012) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/j.1365-2036.2012.04994.x · Cited by 51 · see citing works

Untitled work

(1997) · PubMed · Cited by 50 · see citing works

Recurrent and De Novo Autoimmune Liver Diseases

Mendes, F. D., Couto, C. A., & Levy, C. (2011) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.08.008 · Cited by 49 · see citing works

Treatment of autoimmune liver disease: current and future therapeutic options

Trivedi, P. J., & Hirschfield, G. M. (2013) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313478646 · Cited by 49 · see citing works

An increased risk of urinary tract infection precedes development of primary biliary cirrhosis

Varyani, F. K., West, J., & Card, T. R. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-95 · Cited by 47 · see citing works

Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?)

Tabibian, J. H., & Lindor, K. D. (2014) · Hepatology · doi:10.1002/hep.27180 · Cited by 42 · see citing works

Lipidomic Profiling of Bile in Distinguishing Benign From Malignant Biliary Strictures: A Single-Blinded Pilot Study

Navaneethan, U., Gutierrez, N. G., Venkatesh, P. G. K., Jegadeesan, R., Zhang, R., Jang, S. N., Sanaka, M. R., Vargo, J. J., Parsi, M. A., Feldstein, A. E., et al. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.60 · Cited by 35 · see citing works

Predictive role of anti‐gp210 and anticentromere antibodies in long‐term outcome of primary biliary cirrhosis

Nakamura, M., Komori, A., Ito, M., Kondo, H., Aiba, Y., Migita, K., Nagaoka, S., Ohata, K., Yano, K., Abiru, S., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00244.x · Cited by 34 · see citing works

O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS

Nevens, F., Andreoné, P., Mazzella, G., Strasser, S. I., Bowlus, C. L., Invernizzi, P., Drenth, J. P. H., Pockros, P., Reguła, J., Hansen, B., et al. (2014) · Journal of Hepatology · doi:10.1016/s0168-8278(14)61463-x · Cited by 31 · see citing works

Smoking, family history and urinary tract infection are associated with primary biliary cirrhosis: A meta‐analysis

Liang, Y., Yang, Z., & Zhong, R. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00806.x · Cited by 30 · see citing works

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: Throwing the urso out with the bathwater? # †

Chapman, R. W. (2009) · Hepatology · doi:10.1002/hep.23174 · Cited by 28 · see citing works

Nasobiliary drainage for cholestatic pruritus

Hofmann, A. F., & Huet, P. (2006) · Hepatology · doi:10.1002/hep.21185 · Cited by 21 · see citing works

Autoimmune liver disease

Czaja, A. J. (2009) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328324ed06 · Cited by 21 · see citing works

OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC: Abstract OP02 Table 1

Jones, D., Kowdley, K. V., Chapman, R. W., Burroughs, A. K., Hirschfield, G. M., Schramm, C., Poupon, R. Y., Parés, A. R., Shapiro, D., Pruzanski, M., et al. (2011) · Gut · doi:10.1136/gutjnl-2011-300857b.2 · Cited by 15 · see citing works

Prevalence of non-organ-specific autoantibodies in a rural community from northeastern Brazil: a population-based study

Cunha, L. M., Bittencourt, P. L., Abrantes‐Lemos, C. P., Moreira, A., Almeida, D., Paraná, R., & Andrade, Z. D. A. (2011) · Human Immunology · doi:10.1016/j.humimm.2011.10.001 · Cited by 12 · see citing works

Reflections on Therapeutic Trials in Primary Biliary Cirrhosis * #

Combes, B. (2005) · Hepatology · doi:10.1002/hep.20936 · Cited by 9 · see citing works

The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the faresoid C receptor agonist obeticholic acid in PBC

Kowdley, K. V., Luketic, V., Jones, D., Chapman, R. W., Burroughs, A. K., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., et al. (2011) · Newcastle University ePrints (Newcastle Univesity) · doi:10.25405/ncl.34168236 · Cited by 6 · see citing works

Long-term administration of bezafibrate on primary biliary cirrhosis

Yano, K., 浩之, 加., 森田茂樹, & FURUKAWA, R. (2002) · Kanzo · doi:10.2957/kanzo.43.115 · Cited by 5 · see citing works

P399 PBC MANAGEMENT AMONG CLINICIANS: GAPS IN CLINICAL COMPETENCE AND PRACTICE PERFORMANCE – SURVEY FINDINGS

Bodenheimer, H. C., Jones, D., Peterson, P., & Rudell, E. (2014) · Journal of Hepatology · doi:10.1016/s0168-8278(14)60561-4 · Cited by 1 · see citing works

EASL Clinical Practice Guidelines: autoimmune hepatitis

(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245 · see citing works

Liver regeneration — mechanisms and models to clinical application

Forbes, S. J., & Newsome, P. N. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.97 · Cited by 413 · see citing works

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 347 · see citing works

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double‐blind, randomised, placebo‐controlled, crossover, phase 2a study

Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30319-7 · Cited by 206 · see citing works

Cellular and Molecular Mechanisms of Autoimmune Hepatitis

Webb, G. J., Hirschfield, G. M., Krawitt, E. L., & Gershwin, M. E. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043534 · Cited by 145 · see citing works

Novel therapeutic targets in primary biliary cirrhosis

Dyson, J. K., Hirschfield, G. M., Adams, D. H., Beuers, U., Mann, D. A., Lindor, K. D., & Jones, D. E. J. (2015) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/nrgastro.2015.12 · Cited by 120 · see citing works

The immunogenetics of primary biliary cirrhosis: A comprehensive review

Webb, G. J., Siminovitch, K. A., & Hirschfield, G. M. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.004 · Cited by 118 · see citing works

Protective Effects of Astaxanthin on ConA-Induced Autoimmune Hepatitis by the JNK/p-JNK Pathway-Mediated Inhibition of Autophagy and Apoptosis

Li, J., Xia, Y., Liu, T., Wang, J., Dai, W., Wang, F., Zheng, Y., Chen, K., Li, S., Abudumijiti, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120440 · Cited by 98 · see citing works

Implementation of the Lancet Standing Commission on Liver Disease in the UK

Williams, R. L., Ashton, K., Aspinall, R., Bellis, M. A., Bosanquet, J., Cramp, M., Day, N., Dhawan, A. K., Dillon, J. F., Dyson, J. K., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00680-7 · Cited by 90 · see citing works

Clinical significance of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein level and high‐sensitivity C‐reactive protein concentration in autoimmune hepatitis

Nishikawa, H., Enomoto, H., Iwata, Y., Hasegawa, K., Nakano, C., Takata, R., Nishimura, T., Yoh, K., Aizawa, N., Sakai, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12596 · Cited by 79 · see citing works

The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis

Dyson, J. K., Wilkinson, N., Jopson, L., Mells, G., Bathgate, A., Heneghan, M. A., Neuberger, J., Hirschfield, G. M., Ducker, S. J., The UK‐PBC Consortium, et al. (2016) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.13794 · Cited by 78 · see citing works

The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis

Yang, F., Wang, Q., Wang, Z., Miao, Q., Xiao, X., Tang, R., Chen, X., Bian, Z., Zhang, H., Yang, Y., et al. (2016) · Clinical Reviews in Allergy &amp; Immunology · doi:10.1007/s12016-015-8516-5 · Cited by 71 · see citing works

The immunobiology of mucosal-associated invariant T cell (MAIT) function in primary biliary cholangitis: Regulation by cholic acid-induced Interleukin-7

Jiang, X. W., Lian, M., Li, Y., Zhang, W., Wang, Q., Wei, Y., Zhang, J., Chen, W., Xiao, X., Miao, Q., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.01.007 · Cited by 70 · see citing works

Obeticholic acid for the treatment of primary biliary cirrhosis

Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1092381 · Cited by 65 · see citing works

Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists

Webb, G. J., Rana, A. A., Hodson, J. A., Akhtar, M. Z., Ferguson, J., Neuberger, J., Vierling, J. M., & Hirschfield, G. M. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.09.062 · Cited by 61 · see citing works

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

Dyson, J. K., Wong, L. L., Bigirumurame, T., Hirschfield, G. M., Kendrick, S. F. W., Oo, Y. H., Lohse, A. W., Heneghan, M. A., & Jones, D. E. J. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14968 · Cited by 57 · see citing works

The intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts

Liwinski, T., Heinemann, M., & Schramm, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00936-6 · Cited by 59 · see citing works

Elevated platelet distribution width and red cell distribution width are associated with autoimmune liver diseases

Ustaoglu, M., Aktas, G., Avcıoğlu, U., Bas, B., & Bahceci, B. K. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002296 · Cited by 56 · see citing works

Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis

Deneau, M. R., Mack, C. L., Abdou, R., Amin, M. D., Amir, A. Z., Auth, M. K. H., Bazerbachi, F., Broderick, A. M., Chan, A. C. Y., DiGuglielmo, M., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1251 · Cited by 50 · see citing works

Metabolism of glycerophospholipid, bile acid and retinol is correlated with the early outcomes of autoimmune hepatitis

Zhou, C., Jia, H., Liu, Y., Yu, M., Chang, X., Ba, Y., & Zou, Z. (2016) · Molecular BioSystems · doi:10.1039/c6mb00092d · Cited by 49 · see citing works

Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis

Trivedi, P. J., Scalera, I., Slaney, E., Laing, R. W., Gunson, B. K., Hirschfield, G. M., Schlegel, A. A., Ferguson, J., & Muiesan, P. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.027 · Cited by 47 · see citing works

Treatment of primary sclerosing cholangitis in children

Laborda, T. J., Jensen, M. K., Kavan, M., & Deneau, M. R. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i1.19 · Cited by 42 · see citing works

BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial

Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Richards, D. B., Storey, J. R., Dukes, G. E., Gilchrist, K., Vallow, S., Alexander, G., et al. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0481-9 · Cited by 39 · see citing works

Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study

Muratori, P., Carbone, M., Stangos, G., Perini, L., Lalanne, C., Ronca, V., Cazzagon, N., Bianchi, G. P., Lenzi, M., Floreani, A., et al. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.02.015 · Cited by 34 · see citing works

Early Molecular Stratification of High-risk Primary Biliary Cholangitis

Hardie, C., Green, K., Jopson, L., Millar, B., Innes, B., Pagan, S., Tiniakos, D., Dyson, J., Haniffa, M., Bigley, V., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.021 · Cited by 32 · see citing works

Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course

Deneau, M. R., Perito, E. R., Ricciuto, A., Gupta, N. A., Kamath, B. M., Palle, S. K., Vitola, B. E., Smolka, V., Ferrari, F., Amir, A. Z., et al. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.01.039 · Cited by 23 · see citing works

Limitation of the simplified scoring system for the diagnosis of autoimmune Hepatitis with acute onset

Muratori, P., Granito, A., Lenzi, M., & Muratori, L. (2021) · Liver International · doi:10.1111/liv.14778 · Cited by 23 · see citing works

18F-FAC PET Selectively Images Liver-Infiltrating CD4 and CD8 T Cells in a Mouse Model of Autoimmune Hepatitis

Salas, J. R., Chen, B. Y., Wong, A., Cheng, D., Arnam, J. S. V., Witte, O. N., & Clark, P. M. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210328 · Cited by 22 · see citing works

Dietary Polyphenols Alleviate Autoimmune Liver Disease by Mediating the Intestinal Microenvironment: Challenges and Hopes

Cheng, Z., Wang, Y., & Li, B. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c02654 · Cited by 20 · see citing works

Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015)

Chinese Society of Hepatology, C. S. O. G. &. C. S. O. I. D. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12479 · Cited by 19 · see citing works

Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice

Gee, L. M. V., Barron-Millar, B., Leslie, J., Richardson, C., Zaki, M. Y. W., Luli, S., Burgoyne, R. A., Cameron, R. I. T., Smith, G. R., Brain, J. G., et al. (2023) · The American Journal of Pathology · doi:10.1016/j.ajpath.2022.09.005 · Cited by 18 · see citing works

Obeticholic acid for the treatment of primary biliary cirrhosis

Jones, D. E. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1216784 · Cited by 17 · see citing works

Complex interplay between the immune system, metabolism, and epigenetic factors in autoimmune liver diseases

Xu, Y., Zhao, Z., Yan, E. P., Lian, Z., & Zhang, W. (2023) · Medicine Advances · doi:10.1002/med4.23 · Cited by 18 · see citing works

Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis

Webb, G. J., & Hirschfield, G. M. (2014) · Hepatology · doi:10.1002/hep.27552 · Cited by 15 · see citing works

Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)

Wetten, A., Jones, D. E. J., & Dyson, J. K. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2130750 · Cited by 14 · see citing works

Primary sclerosing cholangitis and the management of uncertainty and complexity

Arndtz, K., & Hirschfield, G. M. (2017) · Frontline Gastroenterology · doi:10.1136/flgastro-2017-100815 · Cited by 14 · see citing works

May Previous Hepatitis B Virus Infection Be Involved in Etiology and Pathogenesis of Autoimmune Liver Diseases?

Николаевич, Б. С., Morozov, S. V., Vinnitskaya, E. V., Сергеевна, С. Е., Борунова, Ж. В., Dorofeev, A., Sandler, Y. G., Германович, С. К., Kostyushev, D. S., Brezgin, S., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01983-5 · Cited by 12 · see citing works

The immunoregulatory effects of total glucosides of peony in autoimmune diseases

Zhao, M., Peng, N., Zhou, Y., Qu, Y., Cao, M., Zou, Q., Yu, Q., Lu, L., & Xiao, F. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae095 · Cited by 11 · see citing works

Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial

Khanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A. M., Newton, J. L., Wilkinson, J. S., Steel, A. J., Bainbridge, J., Stefanetti, R. J., et al. (2018) · Efficacy and Mechanism Evaluation · doi:10.3310/eme05020 · Cited by 12 · see citing works

Living vs deceased donor liver transplantation in cholestatic liver disease: An analysis of the OPTN database

Ziogas, I. A., Alexopoulos, S. P., Matsuoka, L. K., Geevarghese, S. K., Gorden, L. D., Karp, S. J., Perkins, J. D., & Montenovo, M. I. (2020) · Clinical Transplantation · doi:10.1111/ctr.14031 · Cited by 11 · see citing works

Liver disease in the UK

Hirschfield, G. M., Thain, C., Walmsley, M., Brownlee, A. T., & Jones, D. E. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60192-1 · Cited by 11 · see citing works

Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?

Dyson, J. K., & Jones, D. E. J. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.019 · Cited by 10 · see citing works

Advances in clinical detection methods and nanomaterials for autoimmune liver diseases

Chen, J., Zhu, Y., Wang, Q., Ding, J., & Chen, X. (2023) · Nano TransMed · doi:10.1016/j.ntm.2023.100003 · Cited by 8 · see citing works

Elucidating the causal nexus between antibody-mediated immunity and autoimmune diseases: Insights from bidirectional mendelian randomization, gene expression profiling, and drug sensitivity analysis

Chen, J., Wei, C., Huang, S., Wu, S., He, R., Chen, T., Qin, X., Wei, W., Qin, B., Wu, S., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113027 · Cited by 7 · see citing works

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis

Singleton, C., Carter, A., Baker, B. A., Jones, E. S., Green, K., Lammert, C. S., & Nephew, L. D. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18235 · Cited by 6 · see citing works

Gastrointestinal Manifestations of Autoimmune Diseases Requiring Critical Care

Collins‐Yoder, A. (2017) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2017.10.001 · Cited by 6 · see citing works

Predicting Liver Disease Risk Using a Combination of Common Clinical Markers: A Screening Model from Routine Health Check-Up

Wang, Y., Li, Y., Wang, X., Gaćeša, R., Zhang, J., Zhou, L., & Wang, B. (2020) · Disease Markers · doi:10.1155/2020/8460883 · Cited by 6 · see citing works

Editorial: fenofibrate as second‐line therapy in high risk PBC – more answers or more questions?

Jones, D. E., & Hansen, B. E. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13507 · Cited by 6 · see citing works

Clinical trials reimagined

Kwo, P. Y., & Patel, T. C. (2023) · Hepatology · doi:10.1097/hep.0000000000000436 · Cited by 5 · see citing works

Geoepidemiologic variation in outcomes of primary sclerosing cholangitis

Mehta, T. I., Weissman, S. I., Fung, B. M., & Tabibian, J. H. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i4.116 · Cited by 4 · see citing works

Open challenges in the management of autoimmune hepatitis

Gerussi, A., Halliday, N., Carbone, M., Invernizzi, P., & Thorburn, D. (2023) · Minerva Gastroenterology · doi:10.23736/s2724-5895.20.02805-6 · Cited by 4 · see citing works

Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis

Kumar, S. K., Lin, S., & Schold, J. D. (2024) · Hepatology International · doi:10.1007/s12072-024-10733-y · Cited by 3 · see citing works

Trends of autoimmune liver disease inpatient hospitalization and mortality from 2011 to 2017: A United States nationwide analysis

Wakil, A., Muzahim, Y., Awadallah, M., Kumar, V., Mazzaferro, N., Greenberg, P. J., & Pyrsopoulos, N. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i7.1029 · Cited by 2 · see citing works

Circulating suPAR as a noninvasive biomarker of fibrosis and immune activation in autoimmune liver diseases

Zhan, F., 陈添彬, Liang, J., Liu, C., Huang, M., & Jiang, L. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.120831 · Cited by 2 · see citing works

Association between autoimmune liver diseases and chronic hepatitis B: A multivariable Mendelian randomization study in European population

Zhang, W., & Lang, R. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.107984 · Cited by 2 · see citing works

Looking Into the Crystal Ball: Predicting Non-response to Ursodeoxycholic Acid in Primary Biliary Cholangitis

Zimmer, V., & Lammert, F. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.008 · Cited by 2 · see citing works

Ethnic and Racial Differences in Autoimmune Liver Diseases

Freire, A., & Levy, C. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0399-5 · Cited by 2 · see citing works

Protocolo diagnóstico de la elevación crónica de las transaminasas

Ruiz-Bueno, P., Lavín, A. C., Álvarez, S., & García, J. C. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.04.006 · Cited by 2 · see citing works

Primary biliary cholangitis

Dyson, J. K., & Jones, D. E. J. (2020) · doi:10.1093/med/9780198746690.003.0325 · Cited by 2 · see citing works

Autoantibody Profile of Adult Patients With Childhood Onset Type 2 Autoimmune Hepatitis

Woynarowski, M., Woźniak, M., Cukrowská, B., Wierzbicka, A., & Lytton, S. D. (2015) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21907 · Cited by 1 · see citing works

High prevalence of acute onset autoimmune hepatitis in males: A real-life cohort from Northern Italy

Donato, M. F., Rigamonti, C., Monico, S., Vinci, M. R., Colapietro, F., Poggio, P. D., & Colloredo, G. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.09.005

Choledocholithiasis simulating primary sclerosing cholangitis

Korolyov, M. P., Fedotov, L. E., Avanesyan, R. G., Федотов, Б. Л., Lepekhin, G. M., & Amirkhanyan, T. V. (2017) · Grekov s Bulletin of Surgery · doi:10.24884/0042-4625-2017-176-4-93-95

An overview and pathophysiology of liver diseases

Kaur, S., & Tripathi, D. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-99478-1.00001-8

Constructing a protein–protein interaction network for autoimmune liver diseases by integrating pQTL, rQTL, and mediation analyses

Tian, D., Yang, Z., Zhao, L., Zhao, H., Sang, X., Du, S., Luo, Y., Zhang, L., Xu, Y., & Lu, X. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05175-2

Elafibranor in selected patients with primary biliary cholangitis and cirrhosis: An exploratory real-world cohort study

Nuruzade, N., Oruc, U., Konstantis, G., Passenberg, M., Moghadam, A. D., Best, J., Veltkamp, C., Seltsam, F., Schmidt, H., Willuweit, K., et al. (2026) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848261492853

Unmet needs in autoimmune liver diseases.

Kolev, M., Kremer, A. E., Sokollik, C., Gershwin, M. E., & Beretta‐Piccoli, B. T. (2025) · Open Access CRIS of the University of Bern · doi:10.48620/88420

Unmet needs and new models for future trials in autoimmune hepatitis

Jones, D. E., Manns, M. P., Terracciano, L., Torbenson, M. S., & Vierling, J. M. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30043-8 · Cited by 25 · see citing works

自身免疫性肝病基础和临床研究进展

Lingjuan, Z. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/j.issn.1001-5256.2014.05.022 · Cited by 1 · see citing works

Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022

Snijders, R. J. A. L. M., Assis, D. N., Oo, Y. H., Sebode, M., Taubert, R., Willemse, J., Tomsin, B., Lohse, A. W., Drenth, J. P. H., Gevers, T. J. G., et al. (2023) · Liver International · doi:10.1111/liv.15573 · Cited by 15 · see citing works

[Research progress on autoimmune liver disease in 2024].

Zheng, L. H., & Han, Y. (2025) · PubMed · doi:10.3760/cma.j.cn501113-20241214-00620